BURRELL INTERNATIONAL GROUP LLC for EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC )
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 19, 2019 | $10,000 | Replaced |
| 2nd Quarter - Termination | Jul 19, 2019 | $10,000 | Replaced |
| 2nd Quarter - Termination Amendment (this page) | Jul 30, 2019 | $10,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
NDAA - provisions related to biological and chemical defense Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Foreign entity interest: Emergent Biosolutions/Adapt Pharma is a U.S. domestic subsidiary of a foreign parent. All lobbying efforts, while not controlled, supervised, or directed by the parent, benefit the parent tangentially.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBORAH LYNN BURRELL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.